Wall Street Zen Downgrades Tvardi Therapeutics (NASDAQ:TVRD) to Strong Sell

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by equities researchers at Wall Street Zen to a “strong sell” rating in a report released on Saturday.

A number of other analysts also recently commented on TVRD. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research note on Wednesday, July 8th. HC Wainwright began coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They set a “buy” rating and a $9.00 price target for the company. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, July 8th. BTIG Research restated a “buy” rating and issued a $15.00 price objective on shares of Tvardi Therapeutics in a research report on Tuesday, July 7th. Finally, Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Tvardi Therapeutics Stock Performance

NASDAQ:TVRD opened at $3.20 on Friday. Tvardi Therapeutics has a one year low of $1.50 and a one year high of $43.65. The firm has a market cap of $30.02 million, a price-to-earnings ratio of -1.03 and a beta of 0.39. The firm’s fifty day moving average is $3.04 and its two-hundred day moving average is $3.49.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.08). As a group, equities research analysts predict that Tvardi Therapeutics will post -2.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tvardi Therapeutics

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tvardi Therapeutics during the second quarter worth approximately $43,000. Headlands Technologies LLC acquired a new stake in Tvardi Therapeutics in the second quarter valued at approximately $80,000. New York State Common Retirement Fund acquired a new stake in Tvardi Therapeutics in the second quarter valued at approximately $92,000. Finally, Squarepoint Ops LLC acquired a new stake in Tvardi Therapeutics in the third quarter valued at approximately $318,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.